Lasa Supergenerics Limited (BSE: 540702) (NSE: LASA), a vertically integrated group spanning the entire animal and human healthcare value chain, has announced its financial results for the first quarter ended June 30th 2020 (Q1FY21)
Q1FY21 performance overview compared with Q4FY20Â Â
Q1FY21 performance overview compared with Q1FY20Â Â
For first quarter ended June 30th 2020
Revenues from operations for the first quarter ended June 30th, 2020 (Q1FY21) stood at Rs. 54.60 crore.
The Company reported Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) of Rs. 12.20 crore in Q1FY21, as against Rs 9.01 crore in Q4FY20; up 35.4%. The Company’s EBITDA margin stood at 22.34%
The Company reported PAT of Rs. 5.37 crore for Q1FY21.The Company’s PAT margin stood at 9.84%
Earnings per share (EPS) for the quarter ended Q1FY21 stood at Rs. 1.32
The Finance cost reduced by 45% Q-o-Q from Rs. 2.29 crore in Q4FY20 to Rs. 1.29 crore in Q1FY21
Commenting on the performance, Dr. Omkar Herlekar, Chairman – Lasa Supergenerics Limited, said,
“We have reported a good performance in our business in Q1 FY21 despite significant disruptions and ambiguity in the business environment. We are confident that the Company under its strong leadership and planned strategies will navigate through these difficult times. We have substantially brought down the debt.”
